Targeting the transcription factor Myb by small-molecule inhibitors

Sagar Uttarkar, Jonathan Frampton, Karl-heinz Klempnauer

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)
312 Downloads (Pure)


The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.
Original languageEnglish
Pages (from-to)31-35
JournalExperimental Hematology
Early online date23 Dec 2016
Publication statusPublished - 1 Mar 2017


Dive into the research topics of 'Targeting the transcription factor Myb by small-molecule inhibitors'. Together they form a unique fingerprint.

Cite this